OMND — Optimind Pharma Income Statement
0.000.00%
- CA$0.58m
- CA$1.12m
- CA$0.17m
Annual income statement for Optimind Pharma, fiscal year end - February 28th, CAD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2023 February 28th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | fx Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.17 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.214 | -0.14 | -0.173 | 0.161 | 3.26 |
Operating Profit | -0.214 | 0.14 | 0.173 | -0.161 | -3.09 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.214 | -0.025 | 0.131 | -0.172 | -3.09 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.214 | -0.025 | 0.131 | -0.172 | -3.08 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.214 | -0.025 | 0.131 | -0.172 | -3.08 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.214 | -0.025 | 0.131 | -0.172 | -3.08 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.036 | -0.034 | -0.019 | -0.017 | -0.021 |